OncoMatch/Clinical Trials/NCT07202091
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
Is NCT07202091 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Immune Globulin Intravenous and Trimethoprim Sulfamethoxazole for myeloma.
Treatment: Trimethoprim Sulfamethoxazole · Amoxycillin/clavulanic acid · Immune Globulin Intravenous — This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers. We want to know how these different treatments impact on your health and your use of healthcare services. This research project uses an Adaptive Platform Design. This design allows the researchers to compare multiple infection prevention strategies within the same trial at the same time (rather than running separate trials), to analyse results as the trial occurs and to add new research questions during the course of the trial. The treatments that you may receive as part of the study will be determined by which domain(s) of the platform you participate in. By combining data collected within each domain as part of the platform, the researchers can investigate and compare treatment strategies and infection outcomes across a broader range of participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Prior therapy
Must have received: immunoglobulin replacement — prevention of bacterial infections due to hypogammaglobulinaemia
Patients must be receiving Ig (IV or subcutaneous - SCIg) replacement for prevention of bacterial infections due to hypogammaglobulinaemia for at least 6 consecutive months.
Cannot have received: allogeneic haematopoietic stem cell transplantation
Prior or planned allogeneic haematopoietic stem cell transplantation.
Cannot have received: splenectomy
Previous splenectomy.
Lab requirements
Kidney function
Severe renal impairment (estimated or measured creatinine clearance of < 30 mL/min) excluded
Severe renal impairment (estimated or measured creatinine clearance of < 30 mL/min).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify